Insights

Innovative Immuno-oncology STipe Therapeutics leverages a novel approach targeting the STING pathway to develop cancer therapies, indicating an opportunity to provide advanced biotech solutions, research tools, or partnership collaborations in immune-oncology.

Strategic Funding Milestone With over EUR 22 million in funding and recent Series A financing, the company is investing in innovative therapeutic development, creating opportunities for suppliers of research equipment, lab technologies, or clinical trial services.

Leadership Expansion The appointment of a new Chief Scientific Officer underscores a growing research and development focus, suggesting a need for specialized biotech talent, consulting services, or instrumentation to support scientific growth.

Emerging Market Player As a small, dynamic biotech with a focused immuno-oncology mission, STipe presents potential partnership or B2B sales opportunities for niche biotech products, research reagents, or technology platforms tailored to early-stage companies.

Growth and Collaboration The company's recent activities and funding status reflect a growth trajectory, offering chances to engage in strategic alliances, joint ventures, or supply agreements with innovative biotech firms in the cancer therapy space.

STipe Therapeutics Tech Stack

STipe Therapeutics uses 3 technology products and services including Microsoft 365, Angular, TypeScript, and more. Explore STipe Therapeutics's tech stack below.

  • Microsoft 365
    Email
  • Angular
    Javascript Frameworks
  • TypeScript
    Programming Languages

STipe Therapeutics's Email Address Formats

STipe Therapeutics uses at least 1 format(s):
STipe Therapeutics Email FormatsExamplePercentage
FL@stipetherapeutics.comJD@stipetherapeutics.com
44%
First.Last@stipetherapeutics.comJohn.Doe@stipetherapeutics.com
31%
FLast@stipetherapeutics.comJDoe@stipetherapeutics.com
13%
LastF@stipetherapeutics.comDoeJ@stipetherapeutics.com
12%

Frequently Asked Questions

Where is STipe Therapeutics's headquarters located?

Minus sign iconPlus sign icon
STipe Therapeutics's main headquarters is located at South Denmark Denmark. The company has employees across 3 continents, including EuropeAsiaNorth America.

What is STipe Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
STipe Therapeutics's official website is stipetherapeutics.com and has social profiles on LinkedIn.

What is STipe Therapeutics's SIC code NAICS code?

Minus sign iconPlus sign icon
STipe Therapeutics's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does STipe Therapeutics have currently?

Minus sign iconPlus sign icon
As of December 2025, STipe Therapeutics has approximately 22 employees across 3 continents, including EuropeAsiaNorth America. Key team members include Scientific Consultant: E. A.Research Scientist: E. H. N.. Explore STipe Therapeutics's employee directory with LeadIQ.

What industry does STipe Therapeutics belong to?

Minus sign iconPlus sign icon
STipe Therapeutics operates in the Biotechnology Research industry.

What technology does STipe Therapeutics use?

Minus sign iconPlus sign icon
STipe Therapeutics's tech stack includes Microsoft 365AngularTypeScript.

What is STipe Therapeutics's email format?

Minus sign iconPlus sign icon
STipe Therapeutics's email format typically follows the pattern of FL@stipetherapeutics.com. Find more STipe Therapeutics email formats with LeadIQ.

How much funding has STipe Therapeutics raised to date?

Minus sign iconPlus sign icon
As of December 2025, STipe Therapeutics has raised $22M in funding. The last funding round occurred on Sep 30, 2019 for $22M.

When was STipe Therapeutics founded?

Minus sign iconPlus sign icon
STipe Therapeutics was founded in 2018.

STipe Therapeutics

Biotechnology ResearchSouth Denmark, Denmark11-50 Employees

STipe Therapeutics is a privately held biotechnology company with a vision to become a leader in the immune-oncology field, pioneer therapies using a novel aspect of the stimulator of interferon genes (STING) Pathway to target cancer. The Company was spun out from Aarhus University, Denmark in 2018 and concluded a EUR 20 million a Series A financing in September 2019.

JOB RECRUITMENT SCAM ALERT
STipe Therapeutics is aware of a job recruitment scam involving fraudulent human resources recruiters contacting job seekers. The scam includes requesting personal information, promising or requesting money to purchase office equipment, and interacting and conducting false interviews via social media platforms. Please note STipe Therapeutics does not utilize social media platforms to conduct formal job interviews or extend employment offers with job seekers. We encourage job seekers to be aware of this scam and remain vigilant while searching for a job with STipe Therapeutics.

Section iconCompany Overview

Headquarters
South Denmark Denmark
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2018
Employees
11-50

Section iconFunding & Financials

  • $22M

    STipe Therapeutics has raised a total of $22M of funding over 2 rounds. Their latest funding round was raised on Sep 30, 2019 in the amount of $22M.

  • $1M$10M

    STipe Therapeutics's revenue is estimated to be in the range of $1M$10M

Section iconFunding & Financials

  • $22M

    STipe Therapeutics has raised a total of $22M of funding over 2 rounds. Their latest funding round was raised on Sep 30, 2019 in the amount of $22M.

  • $1M$10M

    STipe Therapeutics's revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.